Welcure Drugs & Pharmaceuticals Ltd — Important, 03-09-2025: Company Update

Welcure Drugs & Pharmaceuticals has signed a Letter of Intent with Singapore's Telexcell Trade PTE LTD for a strategic equity investment. Telexcell intends to acquire up to a 25% stake in Welcure at an indicative price of ₹20 per share, which is a premium to the current market price. This all-cash transaction aims to strengthen Welcure's global presence in pharmaceutical and chemical exports, tapping into emerging market opportunities. The deal is subject to due diligence, definitive agreements, and necessary approvals, with completion targeted within 90 days. Investors should note this LOI is non-binding.